EXTON, Pa., Oct. 22, 2019 /PRNewswire/ -- (Booths
#F44 & #F51)—West Pharmaceutical Services, Inc. (NYSE:
WST), a global leader in innovative solutions for injectable drug
administration, today announced two innovative product
offerings at the 2019 PDA Universe of Pre-Filled Syringes and
Injection Devices (PDA PFS). West is launching NovaPure® 3mL
Cartridge components, an addition to its NovaPure product line,
comprised of plunger and lined seal components, specifically
designed for consistent delivery for higher-volume injectable drug
delivery systems. The Company also announced that the SmartDose®
Gen. II 10mL injector, which enables subcutaneous delivery of a
wide range of drug formulation viscosities up to 10mL in volume, is
now available for commercialization. These innovations, along with
highlights from West's high-value product portfolio, Integrated
Solutions Program offering, and latest scientific thought
leadership, will be showcased at this year's PDA PFS meeting, held
October 22-23 in Gothenburg, Sweden.
"Our customers face a number of demands from increasing
regulations and requirements, to evolving patient needs, to an
ever-changing healthcare landscape. Our goal is to simplify their
journey and work by their side to support them with products,
services and solutions. We aim to speed their development and to
help ensure a continuous supply to the market of important
therapies which drive better patient outcomes," said Karen
Flynn, Senior Vice President and Chief Commercial
Officer, West. "The launch of our NovaPure 3mL Cartridge
components line and the enhancements to our SmartDose platform are
the first of many upcoming product launches and updates we'll be
announcing in the coming months to address specific issues we know
our customers are facing as they work to bring innovative, new
injectable medicines to market."
The NovaPure 3mL Cartridge components expand the robust
NovaPure product portfolio which currently includes stoppers and
syringe plungers. NovaPure components embody West's highest quality
standard for components, adhering to scientific, risk-mitigating
Quality by Design (QbD) principles resulting in dimensional control
and consistency, vision inspection and visible particulate control,
and best-in class particle specification. The new components are
specifically designed for 3mL cartridges often used in
autoinjectors and other drug delivery devices. They incorporate
West's premium quality enhancements: Westar® pharmaceutical wash
and sterilization, FluroTec® barrier film, and a comprehensive
data package, and are an ideal choice for sensitive biologic drugs
coming to market.
West developed the SmartDose portfolio of devices to offer
patients with chronic health conditions, who require medication
injections, a reliable, convenient and easy-to-use method for
home-based drug administration. The SmartDose Gen. II 10mL drug
delivery system adheres to the patient's body, so patients can
remain hands-free during the injection, which may range from
minutes to hours. The Company has now completed the development
work to enable up to 10mL of medication injection and is ready for
commercialization.
The well-established scientific and regulatory expertise of West
will be featured in the following educational presentations and
poster sessions at the PDA PFS meeting:
Podium Presentations (Tuesday,
October 22, 2019)
- Excipients Effects on Functionality of Glass and Polymer
Based Pre-filled Syringes (3:10pm
CEST) – Liang Fang, Ph.D., Principal Research
Scientist, West, will present as part of moderated Session
1B on Polymer Containers, to be held
from 2:30pm-4:00pm CEST.
- A Science-Based Recommendation of Elastomer Components for
Biologic Drugs (5:05pm CEST)
– Cathy Zhao, Director,
Scientific Insights Lab, West, will join Session 2C on Novel
Therapeutics, to be held from 4:45pm-6:00pm
CEST.
- Evolving Component Technologies to Meet the Needs of
Cartridge Delivery Applications (5:25pm CEST) – Simon
Cote, Director, Technical Customer Service, and Royce Brockett, Director of Product Management,
Prefilled Systems & Delivery, West, will join Session 2A on
Large Volume Injection, to be held from 4:45pm-6:00pm CEST.
Poster Presentation (Tuesday,
October 22 and Wednesday, October 23,
2019)
- Device Drive Technology Considerations for Large Volume Drug
Delivery (West Booth, during all breaks)
– Tim Allen, Program Director, Self-Injection Systems,
West, will highlight research comparing the mechanisms,
performances and other key considerations of several drive
technologies for subcutaneous drug delivery for large volume
(>2.25mL) wearable devices.
Training Workshop (Wednesday,
October 24 and Thursday, October 25,
2019)
- All About Pre-Filled Syringe Systems – From Initial
Development to Final Fill Finish (9:00am
CEST) – Christa
Jansen-Otten, Director of Global Product Management,
Prefilled Systems & Delivery, West, will join three other
industry leaders for a two-day interactive overview of relevant
practical aspects and trends of developing and processing
pre-filled syringes, including regulatory requirements and health
care practitioner and patient perspectives.
For more information on West's high-quality packaging
technologies and drug delivery solutions, including product
demonstrations, please visit booths #F44 and #F51 at the PDA PFS
meeting or visit us online
at www.westpharma.com.
Trademarks and registered trademarks are the property
of West Pharmaceutical Services, Inc. and/or one of its
subsidiaries, in the United States and other
jurisdictions, unless noted otherwise.
FluroTec® technology is licensed from Daikyo Seiko,
Ltd.
Forward-Looking Statements
Certain forward-looking
statements are included in this press release. They use such
words as "will," "new," "newly," "aim," "speed," "ensure,"
"enables," "upcoming," and other similar terminology. These
statements reflect management's current expectations regarding
future events and operating performance and speak only as of the
date of this release. There is no certainty that actual
results will be achieved in-line with current expectations or that
the new NovaPure® 3mL Cartridge Components and
SmartDose® Gen. II Drug Delivery Platform product
offerings will achieve any particular result. These forward-looking
statements involve a number of risks and uncertainties. The
following are some of the factors that could cause our actual
results to differ materially from those expressed in or underlying
our forward-looking statements: customer decisions to move forward
with our new product offerings, dependence on third-party suppliers
and partners and the ability to meet development milestones with
key customers. These important factors are not all inclusive.
For a description of certain additional factors that could cause
the Company's future results to differ from those expressed in any
such forward-looking statements, see Item 1A, entitled "Risk
Factors," in the Company's Annual Report on Form 10-K for the year
ended December 31, 2018. Except as
required by law or regulation, we undertake no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events, or otherwise.
About West
West Pharmaceutical Services, Inc. is
a leading manufacturer of packaging components and delivery systems
for injectable drugs and healthcare products. Working by the side
of its customers from concept to patient, West creates products
that promote the efficiency, reliability and safety of the world's
pharmaceutical drug supply. West is headquartered in Exton,
Pennsylvania, and supports its
customers from locations in North and South
America, Europe, Asia and Australia. West's
2018 net sales of $1.7 billion reflect the daily use of
approximately 112 million of its components and devices, which are
designed to improve the delivery of healthcare to patients around
the world. For more information, visit www.westpharma.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/west-introduces-novapure-3ml-cartridge-components-and-features-smartdose-gen-ii-10ml-drug-delivery-system-at-pda-universe-of-pre-filled-syringes-and-injection-devices-300942560.html
SOURCE West Pharmaceutical Services, Inc.